Autonomic Nervous System (ANS)

and Heart Rate Variability (HRV)


Autonomic Nervous System (ANS)/Heart Rate Variability (HRV) device is an FDA Cleared Class II medical device used to assess arterial hardening, circulation, heart rate variability, and autonomic nervous system function. 

Our ANS/HRV is a low-cost point-of-care test performed by a MA in primary care to aid in the diagnosis of cardiovascular disease, providing real-time results to providers.

Identify Cardiovascular Risks

Diabetic Cardiomyopathy is a disorder of the heart muscle in people with diabetes. Diabetic cardiomyopathy is a condition where diabetes adversely affects the structure and function of the heart muscle. While traditional cardiovascular diseases are often associated with conditions like high blood pressure or atherosclerosis, diabetic cardiomyopathy occurs independently of these factors. Patients with diabetes Type 2 have up to a 74% increased risk of developing Heart Failure (HF), and diabetic patients with HF are 4x more likely to die than those without HF. Importantly, unrecognized HF is highly prevalent in Type 2 diabetics, with over one quarter (27.7%) of those over 60's having previously undiagnosed HF in one report. Therefore it is one, if not the, most important assessment to be measured for all Type 2 diabetic patients and people with 2 or more comorbidities. 

The Framingham Study Found that Individuals with Asymptomatic Left Ventricular Systolic Dysfunction (LVSD) at Entry had a Nearly 5X Increase in the Risk of Developing Symptomatic HF Compared to those with Normal Left Ventricular Function.

Kannel WB, Gordon T, and National Heart Institute (U.S.) (1968) The Framingham study: An epidemiological investigation of cardiovascular disease. Bethesda, MD., United States. Department of Health, Education, and Welfare, National Institutes of Health.

Heart disease may go undiagnosed until symptoms of myocardial infarction, heart failure, or arrhythmia appear. The goal should be to prevent heart failure symptoms by screening at-risk patients for asymptomatic heart dysfunction and implementing cost-effective interventions in the early stages. Echo is the most common way to diagnose heart failure, but our ANS/HRV can provide an inexpensive early screening for all at-risk patients with a high reimbursement. Also, the cardiorenal axis is a new target for intervention in heart failure. Cardiorenal and metabolic comorbidities are common in most people with diabetes and obesity and the interdependent relationship between the heart and the kidneys is an increasingly important target for intervention in the treatment of heart failure, as addressing both organs together can lead to better outcomes for patients.

Our ANS/HRV test is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). The ANS/HRV graphs the heartbeat as it moves through systolic and diastolic cycles. It tracks deviations in fingertip pressure caused by flexible arteries and produces a tight, regular graph for stiff arteries. Using a proprietary algorithm, the device analyses arterial pulse wave variations and compares them against a large body of research to accurately assess arterial hardening. 

Long COVID Consequences

Long COVID, or post-acute consequences of SARS-CoV-2 infection (PASC), can have implications for the cardiovascular system, particularly the left ventricle of the heart. While the primary respiratory symptoms of COVID-19 are well-documented, the virus's impact on the cardiovascular system can result in lingering effects that affect the left ventricle. Cardiomyopathy in COVID-19 patients refers to a condition where the heart muscle becomes inflamed and weakened due to the viral infection. COVID-19, caused by the SARS-CoV-2 virus, primarily affects the respiratory system, but it can also have significant cardiovascular implications. Cardiomyopathy in COVID-19 is one of the cardiac manifestations that can lead to severe complications. The number of hospitalizations and deaths caused by COVID-19 has reduced significantly due to the population's increasing immunity against severe disease. However, the coronavirus that causes COVID-19, SARS-CoV-2, continues to exist, and it still poses a risk to heart health, especially in people with blocked arteries, hypertension, diabetes, and other predisposing factors. Many people who have recovered from COVID-19 have reported experiencing lingering cardiovascular symptoms such as abnormal heartbeats, dizziness, and shortness of breath.

It's essential for individuals with long COVID, particularly those with cardiovascular symptoms, to be tested in the primary care setting to determine if there is should be more comprehensive imaging studies like echocardiograms to evaluate the structure and function of the left ventricle. Monitoring the left ventricle's health is crucial for developing targeted interventions and treatment plans to address the lingering cardiovascular effects of the virus.

Our ANS/HRV comprehensive test, facilitated by our diagnostics suite, meticulously analyzes various facets of cardiovascular health. It delves into heart rate variability and mean heart rate, providing crucial insights into the intricate dynamics of the cardiovascular system. The examination extends to evaluating arterial elasticity and peripheral arterial stiffness, offering valuable insights into vascular health. Furthermore, the test explores the aging of blood vessels and the efficiency of blood circulation, providing a comprehensive perspective on vascular aging. Additionally, it measures the impact of mental and physical stress on the cardiovascular system, furnishing valuable information on stress resilience. Lastly, the test scrutinizes autonomic nervous system function, contributing to a thorough understanding of the body's regulatory mechanisms. This multifaceted analysis ensures a holistic assessment of cardiovascular well-being.

Features of the tests:

COVID-19 Survivors, Regardless of Infection Severity, are More Likely to Develop Cardiovascular Conditions Such as Heart Failure or Coronary Disease within 30 Days Post-Infection.

Simply Better